Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J. Urol.131(6), 1069–1072 (1984).
   PubMed Web of Science ®Google Scholar
• Ghoneim MA, Ashamallah AK, Awaad HK, Whitmore WF Jr. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J. Urol.134(2), 266–268 (1985).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Muscat J, Geschwind JF. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res.18(3B), 1931–1934 (1998).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer64(12), 2448–2458 (1989).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol.8(6), 1050–1055 (1990).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Bajorin DF. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. Nat. Clin. Pract. Urol.5(9), 484–485 (2008).
   PubMedGoogle Scholar
• North S. Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder? Can. Urol. Assoc. J.2(3), 222–224 (2008).
   PubMedGoogle Scholar
• So A. Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer. Can. Urol. Assoc. J.2(3), 225–227 (2008).
   PubMedGoogle Scholar
• Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J. Urol.24(5), 531–542 (2006).
   PubMedGoogle Scholar
• Suttmann H, Kamradt J, Lehmann J, Stockle M. Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy. BJU Int.100(6), 1225–1228 (2007).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology69(1 Suppl.), 62–79 (2007).
   PubMed Web of Science ®Google Scholar
• Dotan ZA, Kavanagh K, Yossepowitch O et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J. Urol.178(6), 2308–2312 (2007).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349(9), 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Donat SM, Shabsigh A, Savage C et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol.55, 177–186 (2008).
   PubMedGoogle Scholar
• International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet354(9178), 533–540 (1999).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol.155(6), 1903–1906 (1996).
   PubMed Web of Science ®Google Scholar
• Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand. J. Urol. Nephrol.36(6), 419–425 (2002).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48(2), 202–205 (2005).
   PubMed Web of Science ®Google Scholar
• Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol.171(2 Pt 1), 561–569 (2004).
   PubMed Web of Science ®Google Scholar
• Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer115(5), 988–996 (2009).
   PubMed Web of Science ®Google Scholar
• Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol.175(4), 1262–1267 (2006).
   PubMed Web of Science ®Google Scholar
• Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur. Urol.50(6), 1176–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J. Urol.169(1), 110–115 (2003).
   PubMed Web of Science ®Google Scholar
• Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol.145(3), 459–467 (1991).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol.153(1), 47–52 (1995).
   PubMed Web of Science ®Google Scholar
• Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol.155(2), 495–499 (1996).
   PubMed Web of Science ®Google Scholar
• Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol.48(2), 189–199 (2005).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol.148(2 Pt 1), 302–306 (1992).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol.153(1), 47–52 (1995).
   PubMed Web of Science ®Google Scholar
• Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol. Dial. Transplant.16(5), 1042–1046 (2001).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol.133(3), 403–407 (1985).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer42(1), 50–54 (2006).
   PubMed Web of Science ®Google Scholar
• Loehrer PJS, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.10(7), 1066-1073 (1992).
   PubMed Web of Science ®Google Scholar
• Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J. Clin. Oncol.24(35), 5545–5551 (2006).
   PubMed Web of Science ®Google Scholar
• Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 trial. Eur. Urol.52(1), 134–141 (2007).
   PubMed Web of Science ®Google Scholar
• Nogue-Aliguer M, Carles J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer97(9), 2180–2186 (2003).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer100(8), 1639–1645 (2004).
   PubMed Web of Science ®Google Scholar
• Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J. Urol.25(6), 563–571 (2007).
   PubMed Web of Science ®Google Scholar
• Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol.2(10), 502–510 (2005).
   PubMedGoogle Scholar
• Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol.22(6), 1014–1024 (2004).
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med.331(19), 1259–1264 (1994).
   PubMed Web of Science ®Google Scholar
• Esrig D, Spruck CH 3rd, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol.143(5), 1389–1397 (1993).
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol.6(9), 678–686 (2005).
   PubMed Web of Science ®Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl Cancer Inst.90(14), 1072–1079 (1998).
   PubMed Web of Science ®Google Scholar
• Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res.7(8), 2440–2447 (2001).
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br. J. Cancer71(4), 831–835 (1995).
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst.84(16), 1251–1256 (1992).
   PubMed Web of Science ®Google Scholar
• Wild PJ, Kunz-Schughart LA, Stoehr R et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol.27(2), 385–391 (2005).
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Karashima T et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res.6(12), 4866–4873 (2000).
   PubMed Web of Science ®Google Scholar
• Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res.7(7), 1957–1962 (2001).
   PubMed Web of Science ®Google Scholar